Armata Pharmaceuticals ARMP 深 沪
已收盘 09-18 16:00:00 美东时间
4.18
+0.080
+1.95%
华盛通- 最 高4.40
- 今 开4.07
- 成交量 16.06万股
- 最 低 4.00
- 昨 收 4.10
- 总市值 1.55亿
- 52周最高 16.34
- 市盈率 静 --
- 换手率 0.43%
- 52周最低 2.94
- 委 比 -33.33%
- 总股本 3718.20万
- 历史最高 16.34
- 量 比 0.13
- 振 幅 9.76%
- 历史最低 0.8311
- 每 手 1
- 风险率 2.49%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Armata Pharmaceuticals Receives FDA Breakthrough Therapy Designation For Its Intravenously Administered Staphylococcus Aureus Multi-Phage Product Candidate AP-SA02
Designation for adjunct treatment of complicated bacteremia caused by methicillin-sensitive S. aureus ("MSSA") or methicillin-resistant S. aureus ("MRSA"). Breakthrough Therapy designation is intended to expedite the review of medicines that treat a serious or life-threatening condition and have sho...
09-14 19:07
Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02
Designation is driven by compelling Phase 2 clinical data in patients with complicated Staphylococcus aureus bacteremia showing AP-SA02 may offer substantial improvement over available thera...
09-14 19:00
Armata Pharmaceuticals Q2 EPS $(0.27) Beats $(0.45) Estimate, Sales $2.510M Beat $420.000K Estimate
Armata Pharmaceuticals (AMEX:ARMP) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0.45) by 38.64 percent. This is a 40 percent increase over losses of $(0.45) per share from the same period last year. The company reported quarterly sales of $2.510 milli...
08-13 04:29
Why Is Armata Pharma Stock Gaining Monday?
Armata Pharmaceuticals Inc. (NYSE:ARMP) stock is trading higher on Monday after the company announced significant clinical, regulatory, manufacturing, and operational progress supporting the advancement of its lead therapeutic candidate, AP-SA02. The late clinical-stage biotechnology business is mov...
07-21 00:45
Armata股价因超级细菌疗法晚期试验进展而飙升
Armata Pharmaceuticals股价周一上涨，此前该公司表示其实验性超级细菌疗法AP-SA02向启动晚期试验迈出了重要一步。 早盘交易中，...
07-20 23:48
Armata Pharmaceuticals shares are trading higher after the company reported clinical, regulatory, manufacturing, and operational progress advancing AP‑SA02 toward a planned Phase 3 study in complicated Staphylococcus aureus bacteremia.
Armata Pharmaceuticals shares are trading higher after the company reported clinical, regulatory, manufacturing, and operational progress advancing AP‑SA02 toward a planned Phase 3 study in complicated Staphylococcus aureus bacteremia.
07-20 22:35
Armata推进AP-SA02临床与生产进程 计划启动Ⅲ期试验
生物制药公司Armata Pharmaceuticals周一宣布，其在研噬菌体疗法AP-SA02在临床、监管和生产方面均取得关键进展，为计划中的Ⅲ期临床试验...
07-20 22:32
Armata Pharma Receives Agreement From FDA On Agreed Initial Pediatric Study Plan
Fulfills important regulatory milestone for AP-SA02 on the path toward a future BLA and supports expansion into pediatric patients LOS ANGELES, July 13, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on t...
07-13 19:14
Armata Pharma Receives Additional $2.5M Of Non-Dilutive DoD Funding Via Medical Technology Enterprise Consortium, Managed By Naval Medical Research Command
Supports Phase 3 readiness of AP-SA02 Non-dilutive DoD funding totals $28.7M to date LOS ANGELES, June 23, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, patho...
06-23 19:12
Armata Secures New Loan Amid Wider Quarterly Loss
Armata Pharmaceuticals ( ($ARMP) ) has provided an update. On May 13, 2026, Arm...
05-14 06:17
